期刊文献+

用低分子肝素辅助治疗房颤并发脑梗死的效果评价 被引量:1

Effect of Low Molecular Heparin for Adjuvant therapy of Atrial Fibrillation with Cerebral Infarction
下载PDF
导出
摘要 目的 :探讨用低分子肝素辅助治疗房颤并发脑梗死的临床效果。方法 :将2016年1月至2017年1月期间重庆市三峡中心医院收治的68例房颤并发脑梗死患者按随机双盲法分为阿司匹林组与肝素组,每组各有34例患者。用阿司匹林、血栓通和胞二磷胆碱对阿司匹林组患者进行治疗,用低分子肝素对肝素组患者进行治疗。治疗结束后,观察对比两组患者治疗的总有效率和神经功能缺损程度的评分。结果 :肝素组患者治疗的总有效率明显高于阿司匹林组患者,其神经功能缺损程度的评分明显低于阿司匹林组患者,差异具有统计学意义(P<0.05)。结论 :用低分子肝素辅助治疗房颤并发脑梗死可显著提升治疗的效果,改善患者的神经功能。 Objective To study theeffect of low molecular heparin for adjuvant therapy of atrial fibrillation with cerebral infarction. Methods Random selected from Sanxia Central Hospital of Changqing from January 2016 to January 2017 to receive and treat the patients of atrial fibrillation with cerebral infarction in 68 cases as the research object, and were randomly divided into Group A and Group B, 34 cases in each group. Treat group A with Aspilin,Xueshuantong and citicohne, treat group B with low molecular heparin. To compare curative effect and neurological function deficiency scale of two groups after treatment. Results The cure effective rate of group B is higher than group A but neurological function deficiency degree is lower than group A, discrepancy of research results of two groups was statistically significant (P〈 0.05). Conclusion Treat atrial fibrillation with cerebral infarction with low molecular heparin for adjuvant therapy can improve curative effect and neurelogieal function of patients.
作者 刘勇
出处 《当代医药论丛》 2017年第7期25-26,共2页
关键词 房颤 脑梗死 低分子肝素 阿司匹林 atrial fibrillation cerebral infaretian low molecular heparin Aspilin
  • 相关文献

参考文献5

二级参考文献38

  • 1刘明 ,沈玉祥 ,袁建军 ,翟亚萍 ,商保军 .血小板激活及内皮损伤血液标志物对心房颤动血栓栓塞危险性的评价[J].临床心血管病杂志,2005,21(6):341-343. 被引量:13
  • 2王友玲.阵发性房颤患者的临床观察与综合护理干预[J].中华医学杂志,2013,3(5):226.
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation [J]. Ann Intern Med, 2007,146(12):857-867.
  • 4Dempfie CE. D-dimer assays: the current status and new assay tech- nologies[J]. Thromb Res, 2006,118(5):569-571.
  • 5Marin F, Roldan V, Climent VE, et al. Plasma yon Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation [J]. Heart, 2004, 90 (10): 1162-1166.
  • 6Nozawa T, Inoue H, Hirai T, et al. D-dimer level influences throm- boembolic events in patients with atrial fibrillation [J]. lnt J Cardiol, 2006, 109(1): 59-65.
  • 7Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family[J]. Lancet, 1997, 349(9061): 1307-1310.
  • 8Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure [J]. N Engl J Med, 2002, 347(3): 161-167.
  • 9Yamashita T, Seino Y, Ogawa A, et al. N-terminal pro-BNP is a novel biomarker for integrated cardio-renal burden and early risk stratifica- tion in patients admitted for cardiac emergency[J]. J Cardiol, 2010, 55 (3): 377-383.
  • 10Pruszczyk P. N-terminal pro-brain natriuretic peptide as an indicator of right ventricular dysfunction [J]. J Card Fail, 2005, 11 (5 Suppl): S65-69.

共引文献34

同被引文献13

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部